Wu Xupeng, Han Haisong, Zhang Chao, Song Wei
Department of Urology, Jincheng People's Hospital, Jincheng, China.
J Oncol. 2022 Aug 26;2022:6211059. doi: 10.1155/2022/6211059. eCollection 2022.
Several novel androgen receptor antagonists have been introduced into the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). We conducted a meta-analysis to evaluate the survival and safety of the combination therapy of novel androgen receptor antagonist and androgen-deprivation therapy (ADT) in patients with mHSPC.
Electronic databases were searched for randomized controlled trials (RCTs) of ADT combined with novel androgen receptor antagonists compared with ADT alone in men with mHSPC. Revman 5.4 and STATA 14.0 were used to performed the meta-analysis, and hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals (CIs) were used as the measurement indicators of outcome variables.
Six RCTs were eventually identified for meta-analysis. Compared with ADT alone, the combination therapy of novel androgen receptor antagonists and ADT can significantly improve the overall survival (OS) and progression-free survival (PFS), as the pooled HR were 0.66, 95%CI (0.60, 0.72), < 0.00001 and 0.43, 95%CI (0.34, 0.54), < 0.00001, respectively, despite increasing the risk of any serious adverse events (OR: 1.18, 95%CI (1.04, 1.33), =0.008). . This study showed that compared with ADT alone, the combination therapy of novel androgen receptor antagonists and ADT can significantly improve the survival status of mHSPC patients, while it increases the risk of serious adverse events.
几种新型雄激素受体拮抗剂已被引入转移性激素敏感性前列腺癌（mHSPC）的治疗。我们进行了一项荟萃分析，以评估新型雄激素受体拮抗剂与雄激素剥夺治疗（ADT）联合治疗mHSPC患者的生存情况和安全性。
检索电子数据库，查找mHSPC男性患者中ADT联合新型雄激素受体拮抗剂与单纯ADT的随机对照试验（RCT）。使用Revman 5.4和STATA 14.0进行荟萃分析，风险比（HR）和比值比（OR）及其95%置信区间（CI）用作结局变量的测量指标。
最终确定6项RCT进行荟萃分析。与单纯ADT相比，新型雄激素受体拮抗剂与ADT联合治疗可显著改善总生存期（OS）和无进展生存期（PFS），汇总后的HR分别为0.66，95%CI（0.60，0.72），<0.00001和0.43，95%CI（0.34，0.54），<0.00001，尽管任何严重不良事件的风险增加（OR：1.18，95%CI（1.04，1.33），=0.008）。本研究表明，与单纯ADT相比，新型雄激素受体拮抗剂与ADT联合治疗可显著改善mHSPC患者的生存状况，但会增加严重不良事件的风险。
